GlassScriptPhysician profile
Mohamed Shahed
NPI 1922075399
$9,559.23
in general payments reported to CMS, 2019-2025
51 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $612 · 2021: $1,424 · 2022: $2,352 · 2023: $1,880 · 2024: $618 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,703.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,720.62 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $1,628.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $973.36 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Lilly USA, LLC | $480.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $326.57 | 2021-2023 | |
| Amgen INC. | $324.56 | 2019-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.62 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $243.12 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $196.71 | 2019-2023 | Verquvo |
| Xeris Pharmaceuticals, INC. | $191.97 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $185.60 | 2019-2023 | |
| Smith+Nephew, INC. | $181.05 | 2019-2020 | |
| Eisai INC. | $131.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.59 | 2019-2023 | Vyvanse, Trintellix |
| Glaxosmithkline, LLC. | $109.12 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Shahed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.